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Orphan diseases are a great problem for clinicians due to their low 
frequency in different populations and geographic regions [1, 2]. 
Approximately 6,172 unique rare diseases (RDs) are known to exist 
and new ones are discovered each year, 71.9% of which are genetic 
and 69.9% of which are exclusively pediatric onset cases. RDs affect 
between 262.9 and 446.2 million people worldwide and approximately 
17.8–30.3 million people in the European Union [3]. Therefore, RDs 
have become a global public health priority (NGO Committee for 
Rare Diseases. Statements of support to the NGO Committee for 
Rare Diseases. 2016. https://www.ngocommitteerarediseases.org/
statements-of-support/). Another important issue is the high cost 
of the RD diagnostic procedures for the health-care system, which 
frequently cover the evaluation costs of not only the patient, but also 
the patient’s family members, and hence, this should also be taken into 
consideration in the planning of the diagnostic procedure.
The manifestation of orphan diseases is not always fully symptomatic, 
making the clinical diagnosis of specific orphan diseases difficult. 
Moreover, the complexity of the genetic background of RDs is 
challenging [4, 5, 6]. The typical example of a genetic germline 
aberration associated with a different clinical phenotype is the von 
Hippel Lindau disease (VHL) (Online Mendelian Inheritance in Man 
[OMIM] 193300). VHL is an autosomal dominantly inherited syndrome 
(1/36,000 live births), predisposing carriers to the development of highly 
vascularized malignant and benign tumors [7]. The largest groups 
of causative mutations of the VHL gene include missense mutations 
(50%) and deletions of one or more exons (30%). Other described 
defects consist of nonsense mutations, splicing site mutations, micro-
insertions, or micro-deletions [5, 6]. The VHL gene plays a key role in 
the oxygen-sensing pathway in targeting the subunits of the hypoxia-
inducible factor (HIF; a sequence-specific DNA-binding transcription 
factor) for proteasomal degradation [8]. Abnormal interaction of 
mutated VHL-HIF is responsible for the activation of transcription of 
>200 target genes involved in angiogenesis, metabolism, apoptosis, 
and oxygen homeostasis, which determine the different phenotypes 
of the VHL disease [9]. Homozygous germline mutations of the VHL 
gene have been responsible for a specific form of secondary congenital 
erythrocytosis – Chuvash polycythemia (OMIM 2634000; erythrocytosis 
type 2, autosomal recessive).
In 2020, the first Polish family carrying a variant of the VHL gene 
(c.598C>T) associated with Chuvash polycythemia was identified. The 
presence of mutation was confirmed with the help of the 203 gene 
panel next-generation sequencing (NGS) technique in two siblings 
(homozygotes) and in both parents (heterozygotes). The genetic 
diagnostics of Chuvash polycythemia is challenging, especially in infants 
and young children; therefore, diagnostic success is important [10]. 
It is mainly due to the fact that many other genetic variants belonging 
to different metabolic pathways (oxygen sensing, erythropoiesis, and 
oxygen transport) have been identified as the cause of erythrocytosis 
[11]. The recently proposed inherited erythrocytosis-targeted NGS 
panel includes only 21 genes from the relevant pathways [12]. The 
above-mentioned strategy allows reduction in the high cost of the NGS 
procedure. The number of genes studied, however, should be chosen 
cautiously. The usage of a large gene panel and the NGS technique 
allowed to identify other disease-associated genes and, with the 
help of segregation analysis (reverse phenotyping), made it possible 
to associate new symptoms with a well-known disease phenotype 
[13]. On the other hand, it should be always kept in mind that the 
qualification for genetic diagnostics should proceed with a drastic 
selection of patients with erythrocytosis on the basis of an evaluation 
of the erythropoietin blood concentration and the oxygen tension at 
which hemoglobin is 50% saturated (P50) value to exclude hemoglobin 
variants with high oxygen affinity [14].
In conclusion, the application of advanced genetic techniques, including 
NGS studies, is the future of orphan disease diagnostics. The presented 
data concerning the Polish family with Chuvash polycythemia is an 
excellent example of this.
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